Antifolate Effectiveness in Arthritis
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Nov 3, 1999
Trial Information
Current as of June 22, 2025
Completed
Keywords
ClinConnect Summary
Low-dose methotrexate therapy suppresses autoimmune arthritis in human and animal models. We hypothesize that the effect of methotrexate in the treatment of rheumatoid arthritis is due to the inhibition of aminoimidazole-carboxamide ribotide transformylase, a folate-dependent enzyme that catalyzes the last step in the de novo biosynthesis of inosine monophosphate. The resulting accumulation of aminoimidazole carboxamide riboside inhibits adenosine deaminase, therefore interfering with normal adenosine metabolism. It is well known that children with adenosine deaminase deficiency have severe...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individuals starting methotrexate for rheumatoid arthritis.
- • Study subjects should not currently be taking folic acid-containing vitamins.
- Exclusion Criteria:
- • Cancer, renal, or liver disease.
- • Previous use of methotrexate within the past 6 months or current use of folic acid-containing supplements.
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Patients applied
Trial Officials
Sarah L. Morgan, M.D., R.D.
Principal Investigator
University of Alabama Department of Nutrition Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials